KO‘ZNING YUZAKI VA CHUQUR TUZILMALARINING YALLIG‘LANISH KASALLIKLARI: ETIOLOGIYASI, PATOGENEZI, KLINIK KECHISHI, ZAMONAVIY TASHXISLASH VA MIKRODAVOLOVCHI (ANTI-VEGF) IN’EKSIYALAR ASOSIDA DAVOLASH USULLARI, PROFILAKTIKA VA DISPANSERIZATSIYA TIZIMI

Joʻrayeva G. B.


Annotatsiya

Ushbu maqolada inson ko‘zining yuzaki (qovoq, ko‘z yoshi apparati, kon’yunktiva) va chuqur (shox parda, sklera, tomirli parda) tuzilmalariga ta’sir qiluvchi yallig‘lanish kasalliklari keng tahlil qilinadi. Har bir anatomo-funksional tuzilmaning yallig‘lanish holatlari alohida o‘rganilib, ularning etiologik omillari – bakterial, virusli, zamburug‘li va autoimmun sabablar, shuningdek, atrof-muhit va allergik omillar bilan bog‘liqligi yoritiladi. Patogenez bosqichlari, shu jumladan yallig‘lanish mediatorlari, mikrosirkulyatsiyaning buzilishi, immun javob va to‘qima destruksiyasi jarayonlari bayon etiladi. Mazkur maqola oftalmologiyada uchraydigan yallig‘lanish kasalliklarini zamonaviy ilmiy yondashuvlar asosida tashxislash, differensial tashxis qo‘yish va innovatsion davolash strategiyalarini tanlashda amaliy va nazariy ahamiyatga ega bo‘lgan muhim manba sifatida xizmat qiladi.


Adabiyotlar

  1. Kanski J.J., Bowling B. Clinical Ophthalmology: A Systematic Approach. 8th ed. Elsevier, 2016. Journal of Ophthalmology, Vol. 27, pp. 122–134.
  2. Foster C.S., Vitale A.T. Diagnosis and Treatment of Uveitis. Jaypee Brothers Medical Publishers, 2020. Indian Journal of Ophthalmic Practice, Vol. 14(2), pp. 45–56.
  3. Jager R.D. et al. Anti-VEGF agents for the treatment of retinal diseases. N Engl J Med. 2004; 351:2805–2816.
  4. Nussenblatt R.B. The natural history of uveitis. Int Ophthalmol. 1990; 14(5–6):303–308.
  5. World Health Organization. Global data on visual impairments. WHO, 2019.
  6. Rosenfeld P.J. et al. Ranibizumab for neovascular AMD. N Engl J Med. 2006; 355(14):1419–1431.
  7. Smith W. et al. Epidemiology of AMD and risk factors. Ophthalmic Epidemiol. 2001; 8(4):227–239.
  8. Jonas J.B. et al. Retinal vascular diseases and VEGF inhibition. Prog Retin Eye Res. 2005; 24(6):545–567.
  9. Davis J.L. et al. Uveitis in children: management and outcomes. Am J Ophthalmol. 1996; 122(3):311–315.
  10. Tugal-Tutkun I. et al. Pediatric uveitis. J Pediatr Ophthalmol Strabismus. 2003; 40(6):336–342.
  11. Dick A.D. et al. Anti-inflammatory therapy in uveitis. Br J Ophthalmol. 1998; 82(4):386–389.
  12. Tsilimbaris M.K. et al. Intravitreal aflibercept in uveitis. Retina. 2015; 35(11):2285–2292.
  13. Akpek E.K. et al. Ocular surface inflammation: diagnosis and therapy. Curr Opin Allergy Clin Immunol. 2004; 4(5):455–459.
  14. Liew G. et al. Use of intravitreal therapy in retinal diseases. Clin Exp Ophthalmol. 2012; 40(8):749–757.
  15. Suttorp-Schulten M.S.A., Rothova A. The possible impact of uveitis on visual functioning. Br J Ophthalmol. 1996; 80(10):864–868.
  16. Arevalo J.F. et al. Intravitreal bevacizumab for macular edema. Ophthalmology. 2007; 114(10):1860–1867.
  17. Gologorsky D. et al. Comparative effectiveness of anti-VEGF agents. J Comp Eff Res. 2012; 1(3):275–284.